Masatoshi Kudo

Masatoshi Kudo is the leading hepatocellular carcinoma clinician in Japan, who co-led the REFLECT trial with lenvatinib and has contributed to virtually every major phase 3 HCC clinical trial over the past two decades. He chairs the Japan Society of Hepatology liver cancer guidelines and has developed the Japanese staging and treatment algorithm (BCLC modification for Japan/Asia). His research also addresses locoregional therapy optimization, TACE, and integration of systemic therapy with interventional approaches. He is among the most cited HCC clinicians internationally.